Flash Finance

Dr. Agarwal's Health Care LimitedAGARWALEYECorporate

Healthcare Medical Instruments & Supplies Latest results: Jun 2026 11 quarters of data
Consolidated Standalone
₹465.80
MCap ₹14,767 Cr · P/E 318.2
Dr. Agarwal's Health Care Limited — Stock analysis & AI research Dr. Agarwal's Health Care Limited — Multibagger AI analysis Dr. Agarwal's Health Care Limited — Seasonality — best & worst months Dr. Agarwal's Health Care Limited — Technical indicators & charts Dr. Agarwal's Health Care Limited — Technical setup — score, trend, support & resistance Dr. Agarwal's Health Care Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Sales Growth Stocks📋 Stocks With Strong Quarterly Results📋 Small Cap Stocks List 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹383 Cr
Sales · Jun 2026
+26.8% YoY
₹96 Cr
Operating Profit · Jun 2026
+43.1% YoY
25.0%
OPM % · Jun 2026
+13.1% YoY
₹17 Cr
Net Profit · Jun 2026
+64.9% YoY
₹0.53
EPS · Jun 2026
+65.6% YoY

📝 Dr. Agarwal's Health Care Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Dr. Agarwal's Health Care Limited reported revenue of ₹383 crore for the quarter ended June 2026 (Q1 FY27), up 26.8% from ₹302 crore in the same quarter last year, and up 9.9% sequentially over the March 2026 quarter.

Net profit rose 64.9% year-on-year to ₹17 crore, from ₹10 crore. Earnings per share (EPS) came in at ₹0.53.

Operating profit stood at ₹96 crore — an operating margin (OPM) of 25.0%, compared with 22.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dr. Agarwal's Health Care Limited posted revenue of ₹1,294 crore, a growth of 23.9% over FY25, with a net profit of ₹40 crore (up 88.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,374 crore with a net profit of ₹46 crore.

Valuation snapshot

At the current price of ₹465.80, AGARWALEYE has a market capitalisation of ₹14,767 crore and a trailing P/E of about 318.2.

Within the Medical Instruments & Supplies industry, it is the 3rd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 32.33%, foreign institutional investors (FIIs) 49.56%, domestic institutional investors (DIIs) 15.87%, public shareholders 2.24% of Dr. Agarwal's Health Care Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹14,767 Cr
Current Price ?
₹465.8
P/E ?
318.19above ind
Industry P/E ?
100.10
P/B ?
7.41
P/S ?
10.74
P/FCF ?
2,461.18
Enterprise Value ?
₹15,437 Cr
EV/EBITDA ?
45.88
PEG ?
N/A
Earnings Yield ?
0.8%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹1,374 Cr
OPM ?
24.5%
Profit after tax (TTM) ?
₹46 Cr
EPS (TTM) ?
₹1.46
ROCE ?
6.0%
ROE ?
2.3%
ROA ?
1.6%
Growth
Sales — latest qtr ?
₹383 Cr
PAT — latest qtr ?
₹17 Cr
YoY qtr sales growth ?
26.8%
YoY qtr profit growth ?
64.9%
Sales growth (3y) ?
29%
Sales growth (5y) ?
41%
Profit growth (3y) ?
-9%
Profit growth (5y) ?
23%
Financial Health
Debt ?
₹670 Cr
Debt to Equity ?
0.34
Interest Coverage ?
1.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
32.33%
Change in promoter holding ?
-0.10%
Pledged percentage ?
N/A
Market
Return 3 months ?
-4.1%
Return 6 months ?
4.9%

🗓️ Quarterly results (11 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 213225240255268281302309335348383 +26.8% +9.9%
Operating Profit 5567495865736769809296 +43.1% +3.9%
Other Income 1313251027137713 -73.8% +242.0%
Interest 2222232323211917181919 -1.9% -0.2%
Depreciation 3235373839424448485658 +30.1% +2.7%
Profit Before Tax 1524-8112341610201822 +44.3% +25.0%
Net Profit 1017-9-4827105141117 +64.9% +51.5%
EPS ————0.250.850.320.150.440.330.53 +65.6% +60.6%
OPM % 25.8% 29.8% 20.4% 22.7% 24.2% 26.1% 22.1% 22.3% 23.9% 26.4% 25.0% +13.1% -5.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,044 Cr ₹1,294 Cr ₹1,374 Cr +23.9%
Operating Profit ₹245 Cr ₹308 Cr ₹336 Cr +25.5%
OPM % 23.48% 23.79% 24.48% +1.3%
NPM % 2.02% 3.08% 3.38% +52.5%
Other Income ₹44 Cr ₹28 Cr ₹18 Cr -37.1%
Depreciation ₹156 Cr ₹197 Cr ₹210 Cr +25.9%
Interest ₹90 Cr ₹73 Cr ₹73 Cr -18.7%
EBIT ₹89 Cr ₹111 Cr ₹127 Cr +24.9%
PBT ₹39 Cr ₹64 Cr ₹70 Cr +62.3%
Tax ₹12 Cr ₹17 Cr ₹17 Cr +38.9%
Net Profit ₹21 Cr ₹40 Cr ₹46 Cr +88.6%
EPS ₹1.10 ₹1.24 ₹1.45 +12.7%
Material Cost ₹137 Cr ₹334 Cr ₹418 Cr +144.7%
Employee Cost ₹98 Cr ₹177 Cr ₹193 Cr +80.9%
Extraordinary Items ₹-2 Cr ₹-1 Cr ₹0 Cr +72.0%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 893232 +0.0%
Reserves 5541,2181,9021,960 +3.0%
Borrowings 590661568670 +18.0%
Other Liabilities 236298335300 -10.4%
Total Liabilities 1,3882,1872,8372,961 +4.4%
Fixed Assets 9071,3021,5911,922 +20.8%
CWIP 3591829 +61.1%
Investments 187629729615 -15.6%
Other Assets 258248498395 -20.7%
Total Assets 1,3882,1872,8372,961 +4.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 153222208321 +54.3%
Cash from Investing Activity -436-818-577-167 +71.1%
Cash from Financing Activity 316570374-173 -146.3%
Net Cash Flow 33-265-19 -480.0%
Free Cash Flow 7687186 -66.7%
CFO/OP 102%105%81%115% +42.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 24222523 -8.0%
Inventory Days 11913517466 -62.1%
Days Payable 354383375122 -67.5%
Cash Conversion Cycle -210-226-176-32 +81.8%
Working Capital Days -88-79-55-21 +61.8%
ROCE % 10%8%6%6% +0.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 32.43%32.43%32.39%32.35%32.34%32.33% -0.0%
FIIs 59.26%58.13%58.06%57.94%57.96%49.56% -14.5%
DIIs 6.44%7.92%7.78%7.83%7.72%15.87% +105.6%
Public 1.87%1.52%1.78%1.87%1.98%2.24% +13.1%
No. of Shareholders 63,02148,16846,55443,53842,49242,055 -1.0%

⚖️ Peer comparison

Industry: Medical Instruments & Supplies · 3 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 LENSKART LENSKART SOLUTIONS ₹681.90 118,107 180.2 9,634 668 20.8% 6.9% — — 43.3% 274.5%
2 POLYMED Poly Medicure ₹1,720.90 17,443 55.4 2,024 313 22.8% 15.5% 13.9% -5.1% 30.3% -8.4%
3 AGARWALEYE DR AGARWALS ₹475.30 15,068 101.3 2,207 185 28.2% 8.4% 21.6% 52.4% 26.1% 44.8%
❓ Frequently asked questions
What was Dr. Agarwal's Health Care Limited's revenue in Q1 FY27?
Dr. Agarwal's Health Care Limited reported revenue of ₹383 crore for the quarter ended June 2026 (Q1 FY27), up 26.8% from ₹302 crore in the same quarter last year, and up 9.9% sequentially over the March 2026 quarter.
What was Dr. Agarwal's Health Care Limited's net profit in Q1 FY27?
Net profit rose 64.9% year-on-year to ₹17 crore, from ₹10 crore. Earnings per share (EPS) came in at ₹0.53.
What is AGARWALEYE's market capitalisation and P/E ratio?
At the current price of ₹465.80, AGARWALEYE has a market capitalisation of ₹14,767 crore and a trailing P/E of about 318.2.
Who owns Dr. Agarwal's Health Care Limited? (shareholding pattern)
As of Sep 2026, promoters held 32.33%, foreign institutional investors (FIIs) 49.56%, domestic institutional investors (DIIs) 15.87%, public shareholders 2.24% of Dr. Agarwal's Health Care Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI